Published in Proc Natl Acad Sci U S A on October 28, 1997
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev (2004) 2.60
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun (1999) 1.68
Applications of biological pores in nanomedicine, sensing, and nanoelectronics. Curr Opin Biotechnol (2010) 1.66
Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells. Proc Natl Acad Sci U S A (1998) 1.19
Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol (1999) 1.06
Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem (2009) 1.06
Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. Infect Immun (1999) 1.04
Model of the toxic complex of anthrax: responsive conformational changes in both the lethal factor and the protective antigen heptamer. Protein Sci (2006) 0.95
Injection of Staphylococcus aureus EDIN by the Bacillus anthracis protective antigen machinery induces vascular permeability. Infect Immun (2009) 0.92
Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proc Natl Acad Sci U S A (2000) 0.91
Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis. Infect Immun (1999) 0.90
Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway. Infect Immun (2002) 0.86
The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines. J Virol (2003) 0.81
Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant. J Immunol (2010) 0.81
Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins (Basel) (2016) 0.80
Obstructing toxin pathways by targeted pore blockage. Chem Rev (2012) 0.80
NAD+-Glycohydrolase Promotes Intracellular Survival of Group A Streptococcus. PLoS Pathog (2016) 0.79
Channel-forming bacterial toxins in biosensing and macromolecule delivery. Toxins (Basel) (2014) 0.77
Both CD4+ and CD8+ T cells respond to antigens fused to anthrax lethal toxin. Infect Immun (2008) 0.77
Antigen delivered by anthrax lethal toxin induces the development of memory CD8+ T cells that can be rapidly boosted and display effector functions. Infect Immun (2007) 0.76
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A (1982) 10.36
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol (1989) 8.84
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 8.49
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med (1984) 6.27
Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem (1986) 5.86
Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med (1981) 5.82
Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol (1984) 5.57
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 4.72
A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 4.64
Observations on experimental anthrax; demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature (1954) 4.56
Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J Biol Chem (1994) 4.40
The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol (1993) 4.35
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A (1996) 4.11
Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology (1986) 3.59
Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci U S A (1989) 3.54
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature (1990) 3.15
Production and purification of anthrax toxin. Methods Enzymol (1988) 3.04
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol Microbiol (1995) 2.96
A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today (1996) 2.67
Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science (1996) 2.65
A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem (1989) 2.31
Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem (1993) 2.23
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes. J Exp Med (1991) 2.01
Anthrax toxic complex. Fed Proc (1967) 1.84
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun (1994) 1.84
pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol Microbiol (1993) 1.81
Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem (1992) 1.71
Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J Immunol (1995) 1.58
Purification of the third factor of anthrax toxin. J Gen Microbiol (1962) 1.56
Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis. Gene (1986) 1.51
The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J Biol Chem (1994) 1.47
Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J Immunol (1992) 1.46
Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med (1992) 1.46
Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc Natl Acad Sci U S A (1996) 1.44
In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol (1996) 1.33
Expression of a mutant, full-length form of diphtheria toxin in Escherichia coli. Infect Immun (1987) 1.21
Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu Rev Immunol (1994) 1.20
Functional characterization of protease-treated Bacillus anthracis protective antigen. J Biol Chem (1992) 1.20
Efficiency and effectiveness of cloned virus-specific cytotoxic T lymphocytes in vivo. J Immunol (1989) 1.19
Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. J Cell Biol (1991) 1.18
Cell-invasive activity of epitope-tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T cells. Infect Immun (1995) 1.17
Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells. J Biol Chem (1994) 1.10
Targeted delivery of peptide epitopes to class I major histocompatibility molecules by a modified Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1993) 1.03
Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine (1995) 1.00
Entry of diphtheria toxin-protein A chimeras into cells. J Biol Chem (1991) 0.94
Membrane translocation of diphtheria toxin carrying passenger protein domains. Infect Immun (1992) 0.89
Presentation of an exogenous antigen by major histocompatibility complex class I molecules. Eur J Immunol (1994) 0.88
Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J Immunol (1994) 0.83
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol (Noisy-le-grand) (1995) 0.76
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 10.53
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A (1982) 10.36
Crystal structure of the anthrax toxin protective antigen. Nature (1997) 6.63
Pertussis toxin gene: nucleotide sequence and genetic organization. Science (1986) 6.02
The antigenic structure of proteins: a reappraisal. Annu Rev Immunol (1984) 5.31
T-cell antigenic sites tend to be amphipathic structures. Proc Natl Acad Sci U S A (1985) 5.05
Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J Immunol (1987) 4.95
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem (1992) 4.87
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 4.75
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 4.72
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A (1996) 4.11
Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J Mol Biol (1987) 4.07
Crystal structure of the anthrax lethal factor. Nature (2001) 3.75
Intrinsic and extrinsic factors in protein antigenic structure. Science (1985) 3.54
Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa. Infect Immun (1976) 3.45
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature (1990) 3.15
Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest (1994) 3.12
Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene (1988) 3.10
Production and purification of anthrax toxin. Methods Enzymol (1988) 3.04
Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun (1995) 2.87
Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv Cyclic Nucleotide Protein Phosphorylation Res (1984) 2.86
Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun (1984) 2.70
Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun (1988) 2.69
Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol (1994) 2.65
Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci U S A (1993) 2.65
Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun (1986) 2.63
Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun (1988) 2.63
Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A (1988) 2.60
Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature (1988) 2.56
Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr Purif (2000) 2.52
Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. J Bacteriol (1993) 2.46
Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science (1993) 2.35
Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A (1998) 2.33
A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science (1989) 2.32
Cloning of the protective antigen gene of Bacillus anthracis. Cell (1983) 2.31
A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem (1989) 2.31
Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science (1987) 2.24
Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem (1993) 2.23
Characterization of the subunit structure of the ribonucleic acid genome of influenza virus. J Virol (1971) 2.22
Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol (1991) 2.17
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology (1996) 2.16
The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. J Immunol (1979) 2.15
Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J Immunol (1992) 2.14
Association of diphtheria toxin with Vero cells. Demonstration of a receptor. J Biol Chem (1978) 2.13
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
Distinct H-2-linked Ir genes control both antibody and T cell responses to different determinants on the same antigen, myoglobin. Proc Natl Acad Sci U S A (1979) 2.06
Inhibition of protein synthesis by Shiga toxin: activation of the toxin and inhibition of peptide elongation. FEBS Lett (1980) 2.05
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect Immun (1993) 1.97
Receptor-mediated internalization and degradation of diphtheria toxin by monkey kidney cells. J Biol Chem (1979) 1.94
Antigen conformation determines processing requirements for T-cell activation. Proc Natl Acad Sci U S A (1984) 1.94
Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J Biol Chem (1989) 1.93
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene (1988) 1.90
Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science (1992) 1.89
Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J Exp Med (1986) 1.89
Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol (1994) 1.87
Transcriptional regulation of the protective antigen gene of Bacillus anthracis. Infect Immun (1989) 1.86
Computer support for elderly women with breast cancer. JAMA (1998) 1.86
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun (1994) 1.84
Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (1989) 1.80
Isolation and characterization of spontaneous avirulent variants of Histoplasma capsulatum. Infect Immun (1987) 1.78
Optochin resistance in Streptococcus pneumoniae: mechanism, significance, and clinical implications. J Infect Dis (2001) 1.78
Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun (1990) 1.78
Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med (1996) 1.78
The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest (1998) 1.77
Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol (1984) 1.75
Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J Ind Microbiol Biotechnol (2002) 1.75
Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun (2001) 1.75
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem (2001) 1.73
CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol (1995) 1.72
Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem (1992) 1.71
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun (1999) 1.68
T cell clones to two major T cell epitopes of myoglobin: effect of I-A/I-E restriction on epitope dominance. J Immunol (1985) 1.66
Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol (1989) 1.66
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med (1998) 1.64
Molecular cloning of pertussis toxin genes. Nucleic Acids Res (1986) 1.64
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A (1999) 1.63
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol (1989) 1.63
Effect of choline chloride in allergen-induced mouse model of airway inflammation. Eur Respir J (2007) 1.62
A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol (1992) 1.62
Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol (1988) 1.61
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis (1996) 1.61